Limits...
Association between P16INK4a promoter methylation and HNSCC: a meta-analysis of 21 published studies.

Shi H, Chen X, Lu C, Gu C, Jiang H, Meng R, Niu X, Huang Y, Lu M - PLoS ONE (2015)

Bottom Line: Therefore, we conducted a meta-analysis to better identify the association.A total of twenty-one studies with 1155 cases and 1017 controls were included in the meta-analysis.This meta-analysis of 21 published studies identified that aberrant methylation of p16INK4a promoter was found to be significantly associated with HNSCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

ABSTRACT

Background: The p16INK4a is an important tumor suppressor gene (TSG) and aberrant methylation of promoter is known to be a major inactivation mechanism of the tumor suppressor and tumor-related genes. Aberrant TSG methylation was considered an important epigenetic silencing mechanism in the progression of head and neck squamous cell carcinoma (HNSCC). However, some studies have reported differences in the methylation frequencies of P16INK4a promoter between cancer and the corresponding control group. Therefore, we conducted a meta-analysis to better identify the association.

Methods: PubMed, Ovid, ISI Web of Science, and EMBASE were searched to identify eligible studies to evaluate the association of p16INK4a promoter methylation and HNSCC. Odds ratio (ORs) and 95% confidence intervals (95%CI) were calculated to evaluate the strength of association between p16INK4a promoter methylation and HNSCC.

Results: A total of twenty-one studies with 1155 cases and 1017 controls were included in the meta-analysis. The frequencies of p16INK4a promoter methylation in the cancer group were significantly higher than those in the control group (cancer group: median: 46.67%, range = 7.84%-95.12%; control group: median: 18.37%, range = 0-83.33%; respectively). The pooled odds ratio was 3.37 (95%CI = 2.32-4.90) in the cancer group versus the corresponding control group under the random-effects model.

Conclusion: This meta-analysis of 21 published studies identified that aberrant methylation of p16INK4a promoter was found to be significantly associated with HNSCC.

No MeSH data available.


Related in: MedlinePlus

Selection of studies in the meta-analysis.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4383544&req=5

pone.0122302.g001: Selection of studies in the meta-analysis.

Mentions: A study included in the meta-analysis had to meet the following criteria: (1) studies with evaluating the association between p16INK4a promoter methylation frequency and HNSCC, (2) case-control study or providing the case and the control cases, (3) providing the p16INK4a promoter methylation frequency in case and control groups, (4) specimens of HNSCC were surgically respected primary tumor sample. Firstly, the titles and abstracts of initial searching articles were evaluated for whether it met the inclusion criteria. Then all potentially relevant articles were evaluated on full-text paper. If the results of a study were published more than once, only the most complete and up-to-date information were included in the meta-analysis. The study selection process was shown in Fig 1. Finally, a total of 21 studies (PubMed 13, Web of Science 7, Ovid 1) which contain 1155 cases and 1017 controls were included in our meta-analysis.


Association between P16INK4a promoter methylation and HNSCC: a meta-analysis of 21 published studies.

Shi H, Chen X, Lu C, Gu C, Jiang H, Meng R, Niu X, Huang Y, Lu M - PLoS ONE (2015)

Selection of studies in the meta-analysis.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4383544&req=5

pone.0122302.g001: Selection of studies in the meta-analysis.
Mentions: A study included in the meta-analysis had to meet the following criteria: (1) studies with evaluating the association between p16INK4a promoter methylation frequency and HNSCC, (2) case-control study or providing the case and the control cases, (3) providing the p16INK4a promoter methylation frequency in case and control groups, (4) specimens of HNSCC were surgically respected primary tumor sample. Firstly, the titles and abstracts of initial searching articles were evaluated for whether it met the inclusion criteria. Then all potentially relevant articles were evaluated on full-text paper. If the results of a study were published more than once, only the most complete and up-to-date information were included in the meta-analysis. The study selection process was shown in Fig 1. Finally, a total of 21 studies (PubMed 13, Web of Science 7, Ovid 1) which contain 1155 cases and 1017 controls were included in our meta-analysis.

Bottom Line: Therefore, we conducted a meta-analysis to better identify the association.A total of twenty-one studies with 1155 cases and 1017 controls were included in the meta-analysis.This meta-analysis of 21 published studies identified that aberrant methylation of p16INK4a promoter was found to be significantly associated with HNSCC.

View Article: PubMed Central - PubMed

Affiliation: Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

ABSTRACT

Background: The p16INK4a is an important tumor suppressor gene (TSG) and aberrant methylation of promoter is known to be a major inactivation mechanism of the tumor suppressor and tumor-related genes. Aberrant TSG methylation was considered an important epigenetic silencing mechanism in the progression of head and neck squamous cell carcinoma (HNSCC). However, some studies have reported differences in the methylation frequencies of P16INK4a promoter between cancer and the corresponding control group. Therefore, we conducted a meta-analysis to better identify the association.

Methods: PubMed, Ovid, ISI Web of Science, and EMBASE were searched to identify eligible studies to evaluate the association of p16INK4a promoter methylation and HNSCC. Odds ratio (ORs) and 95% confidence intervals (95%CI) were calculated to evaluate the strength of association between p16INK4a promoter methylation and HNSCC.

Results: A total of twenty-one studies with 1155 cases and 1017 controls were included in the meta-analysis. The frequencies of p16INK4a promoter methylation in the cancer group were significantly higher than those in the control group (cancer group: median: 46.67%, range = 7.84%-95.12%; control group: median: 18.37%, range = 0-83.33%; respectively). The pooled odds ratio was 3.37 (95%CI = 2.32-4.90) in the cancer group versus the corresponding control group under the random-effects model.

Conclusion: This meta-analysis of 21 published studies identified that aberrant methylation of p16INK4a promoter was found to be significantly associated with HNSCC.

No MeSH data available.


Related in: MedlinePlus